构建美国COVID-19疫苗有效性项目:既往成功与未来方向
COVID-19疫苗最初基于随机对照试验(RCT)的安全性、免疫原性和临床效力数据于2020年12月在美国获授权。CDC的COVID-19疫苗有效性(VE)项目旨在提供及时、稳健的数据,以支持疫苗接种的持续政策决策和实施,并包括研究从感染到危重症的疾病谱的VE平台。自2021年以来,CDC COVID-19 VE平台在众多疫苗政策决策中发挥了关键作用,并将在疫苗项目从应急响应转向常规接种程序时继续发挥关键作用。
要点
- 真实世界VE数据可补充RCT未覆盖人群、变异株、接种后时间延长及既往感染水平升高情况下的信息。
- CDC COVID-19 VE项目的目标是提供及时稳健的数据以支持疫苗接种政策决策和实施。
- VE估计面临挑战,包括准确确定接种史、结局状态、既往感染率变化、新变异株出现及绝对与相对VE指标的解释。
核心结论
- CDC COVID-19 VE平台自2021年以来在众多疫苗政策决策中发挥关键作用,并将在疫苗项目转向常规接种程序时继续发挥关键作用。
研究设计与样本
- 原文为描述CDC COVID-19疫苗有效性项目的综述,未报告系统检索范围或样本量。
主要发现
- COVID-19疫苗最初基于RCT的安全性、免疫原性和临床效力数据于2020年12月在美国获授权。
- 真实世界VE数据可提供RCT未纳入人群(如养老院居民)、新SARS-CoV-2变异株、接种后时间延长及既往感染水平升高人群中的疫苗效果信息。
- CDC COVID-19 VE项目包括研究从感染到危重症疾病谱的VE平台。
- VE估计的挑战包括准确确定接种史、结局状态、既往感染率变化、新变异株出现及绝对与相对VE指标的解释。
关键数值与推荐
- 原文未报告具体VE数值、推荐条款或 GRADE 分级。
临床怎么用
- 原文未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
COVID-19 vaccines were originally authorized in the United States in December 2020 on the basis of safety, immunogenicity, and clinical efficacy data from randomized controlled trials (RCTs). However, real-world vaccine effectiveness (VE) data are necessary to provide information on how the vaccines work in populations not included in the RCTs (e.g., nursing home residents), against new SARS-CoV-2 variants, with increasing time since vaccination, and in populations with increasing levels of prior infection. The goal of CDC's COVID-19 VE program is to provide timely and robust data to support ongoing policy decisions and implementation of vaccination and includes VE platforms to study the spectrum of illness, from infection to critical illness. Challenges to estimating VE include accurate ascertainment of vaccination history, outcome status, changing rates of prior infection, emergence of new variants, and appropriate interpretation of absolute and relative VE measures. CDC COVID-19 VE platforms have played a pivotal role in numerous vaccine policy decisions since 2021 and will continue to play a key role in future decisions as the vaccine program moves from an emergency response to a routine schedule.
引用
- Link-Gelles R, Britton A, Fleming-Dutra KE, et al. Building the U.S. COVID-19 vaccine effectiveness program: Past successes and future directions. Vaccine. 2023. PMID: 38129285. doi:10.1016/j.vaccine.2023.12.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。